BIO in tu­mult as CEO abrupt­ly ex­its; Some good PhI­II news; Da­ta is­sues still plague No­var­tis' gene ther­a­py; Hot tar­gets for M&A?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Many thanks to all those who turned up at the EU­BIO event in Lon­don this week — the whole team is now bask­ing in the pos­i­tive feed­back we got and the pho­tos are giv­ing me FO­MO. End­points is look­ing to bring these in-per­son gath­er­ings to many more cor­ners of the world. Stay tuned.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.